Cargando…

Further evidence of clinical benefit associated with participation in phase I oncology trials

Detalles Bibliográficos
Autor principal:	Markman, M
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2275490/ https://www.ncbi.nlm.nih.gov/pubmed/18349816 http://dx.doi.org/10.1038/sj.bjc.6604206

Ejemplares similares

Clinical Predictors of Early Trial Discontinuation for Patients Participating in Phase I Clinical Trials in Oncology
por: Douma, Joeri A. J., et al.
Publicado: (2021)

Communication about the Risks and Benefits of Phase I Pediatric Oncology Trials
por: Hazen, Rebecca A., et al.
Publicado: (2015)

Exploration of potential risk factors for COVID-19 severity in patients participating in oncology clinical trials
por: Mohiuddin, Md, et al.
Publicado: (2021)

Recruitment, outcomes, and toxicity trends in phase I oncology trials: Six‐year experience in a large institution
por: Menon, Siddharth, et al.
Publicado: (2021)

The Evolution of Clinical Trials in Oncology: Defining Who Benefits from New Drugs Using Innovative Study Designs
por: Goldberg, Richard M., et al.
Publicado: (2017)

Is It Time to Inform This Patient that Further Antineoplastic Drug Therapy Will Not Be of Clinical Value?
por: Markman, Maurie
Publicado: (2010)

Clinical Trials in Oncology and Defining Benefit
por: Sorscher, Steven
Publicado: (2017)

Connecting Cardiovascular Disease and Dementia: Further Evidence
por: Paciaroni, Maurizio, et al.
Publicado: (2013)

Further evidence for the use of aspirin in COVID-19
por: Tantry, Udaya S., et al.
Publicado: (2022)

Spotlight on landmark oncology trials: the latest evidence and novel trial designs
por: Earl, Helena, et al.
Publicado: (2017)

Risk and surrogate benefit for pediatric Phase I trials in oncology: A systematic review with meta-analysis
por: Waligora, Marcin, et al.
Publicado: (2018)

Endpoint surrogacy in oncology Phase 3 randomised controlled trials
por: Zhang, Jianrong, et al.
Publicado: (2020)

The Importance of Endpoints in Oncology Clinical Trials
por: Faiman, Beth
Publicado: (2023)

Evidence-based medicine: clinical utility of PET in oncology
por: Miles, K. A.
Publicado: (2015)

Phases I–III Clinical Trials Using Adult Stem Cells
por: Gimble, Jeffrey M., et al.
Publicado: (2011)

Increasing patient participation in oncology clinical trials
por: Chen, Jie, et al.
Publicado: (2022)

Evaluating Long-Term Benefits of Chronic Azithromycin. Furthering Our Quest for Precision Medicine
por: Saiman, Lisa, et al.
Publicado: (2020)

Early mortality and overall survival in oncology phase I trial participants: can we improve patient selection?
por: Chau, Nicole G, et al.
Publicado: (2011)

Cardio-Oncology: mechanisms of cardiovascular toxicity
por: Markman, Timothy M., et al.
Publicado: (2018)

Cardio-oncology: management of cardiovascular toxicity
por: Markman, Timothy M., et al.
Publicado: (2019)

Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors
por: Subbiah, Ishwaria M., et al.
Publicado: (2018)

Pharmacogenomics Testing in Phase I Oncology Clinical Trials: Constructive Criticism Is Warranted
por: Sissung, Tristan M., et al.
Publicado: (2022)

Screening for Aortic Aneurysm: Further Evidence is Required to Clarify the Issue
por: Hozawa, Atsushi
Publicado: (2021)

Benefits of Participation in Clinical Trials: An Umbrella Review
por: Bouzalmate-Hajjaj, Amira, et al.
Publicado: (2022)

Advanced Science–Growing Further and Further
por: Severing, Kirsten
Publicado: (2019)

Can Precision Oncology Benefit Patients With Cancers of Unknown Primary?
por: Rassy, Elie, et al.
Publicado: (2023)

Association of Perceived Benefit or Burden of Research Participation With Participants’ Withdrawal From Cancer Clinical Trials
por: Ulrich, Connie M., et al.
Publicado: (2022)

Informal professionalization of healthy participants in phase I clinical trials in Russia
por: Zvonareva, Olga, et al.
Publicado: (2019)

Diabetic Retinopathy in 2011: Further Insights From New Epidemiological Studies and Clinical Trials
por: Lamoureux, Ecosse L., et al.
Publicado: (2011)

Oncology Clinical Trials in Africa: Emerging and Operational Issues
por: Odedina, Folakemi T., et al.
Publicado: (2020)

Patient motivations surrounding participation in phase I and phase II clinical trials of cancer chemotherapy
por: Nurgat, Z A, et al.
Publicado: (2005)

Personalized prevention in oncology: integrating the current approaches for the benefit of population health
por: Boccia, Stefania, et al.
Publicado: (2022)

Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

First Evidence of Clinical Benefit of Robotically Driven Catheter Ablation or an Outlayer?
por: Almendral, Jesús
Publicado: (2014)

Normal reference range values in adult echocardiography: Further evidence that race matters
por: Shah, Benoy Nalin
Publicado: (2016)

Further evidence for the genetic association between CACNA1I and schizophrenia
por: Xie, Yijun, et al.
Publicado: (2018)

Reach further
por: Christiansen, Jens Sandahl
Publicado: (2012)

Perceptions and Referral Trends into Phase I Oncology Trials: Results of a Clinical Survey
por: Brunetto, Andre, et al.
Publicado: (2011)

Further evidence supports the clinical utility of sperm DNA fragmentation testing in male infertility workup and assisted reproductive technology
por: Esteves, Sandro C., et al.
Publicado: (2017)

Qualitative study investigating the underlying motivations of healthy participants in phase I clinical trials
por: Manton, Kerry J, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qlfggtr5vd4nijabt0bj0a4r6i